GAU-1815 #

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

SUITE 600

1100 NEW YORK AVENUE, N.W.

WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE (202) 371-2540, (202) 371-6566



MAR G

LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C MILLONIG
STEVEN R LUDWIG
MICHAEL V. MESSINGER
JUDITH U KIM*
KEITH KIND*
TIMOTHY J SHEA, JR*
DONALD R MCPHAIL
PATRICK E GARRETT
BARBARA A PARVIS
MICHAEL A RAHMAN*
STEPHEN G. WHITESIDE*

RICK A TOERING*

JEFFREY T HELVEY*

DUANE S. KOBAYASHI
RICHARD A DUNNING, JR

KIMBERLIN M TOOHEY

RALPH P ALBRECHT

HEIDI L KRAUS*

JEFFREY R KURIN*

CARL B MASSEY, JR*

RAYMOND MILLIEN*

PATRICK D. O'BRIEN*

BRIAN S ROSENBLOOM*

Donald J Featherstone**
Lawrence B Bugaisky**
Karen R Markowicz**
Grant E Reed**

*BAR OTHER THAN DIC
**REGISTERED PATENT AGENTS

WRITER'S DIRECT NUMBER.

INTERNET ADDRESS

March 4, 1998

Assistant Commissioner for Patents Washington, D.C. 20231

Re: U

U.S. Continuation Patent Application

Appl. No. 08/836,576; Filed: September 9, 1997

For: Adjuvant for Vaccine Composition

Inventors:

HAENSLER et al.

Our Ref:

0725.0100001/SLF/GER

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. First Supplemental Information Disclosure Statement and Fee Under 37 C.F.R. § 1.97(c);
- 2. Form PTO-1449 two (2) pages, citing four (4) documents;
- 3. A copy of each of the four (4) cited documents;

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Assistant Commissioner for Patents March 4, 1998 Page 2

4. Our Check No. 21223 in the amount of \$240.00 to cover:

\$240.00 Submission of an IDS (37 C.F.R. § 1.97(c)); and

5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Grant F. Reed

Agent for Applicants Registration No. 41,264

0100001 pto

7 3/23/98

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

HAENSLER et al.

Appl. No. 08/836,576

Filed: September 9, 1997

For: Adjuvant For a Vaccine

Composition

Art Unit: 1815

Evaminar

Brumback, D.

Atty. Docket: 0725.0100001/SLF/GER

First Supplemental Information Disclosure Statement and Fee Under 37 C.F.R. § 1.97(c)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each of these documents is provided.

The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in the Applicants' Information Disclosure Statement filed on October 17, 1997 in connection with the above-captioned application.

The Examiner is also referred to the following co-pending U.S. patent applications, which

are directed to related technical subject matter: Appl. No. 08/903,978, filed July 31, 1997, which is a continuation application of Appl. No. 08/466,244, filed June 6, 1995. The identification of 240.00 gp these U.S. patent applications is not to be construed as a waiver of secrecy as to these applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that an exhaustive search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120, 1138 OG 37, 38 (May 19, 1992).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

In accordance with 37 C.F.R. § 1.97(c), fee payment under 37 C.F.R. § 1.17(p) is provided in our accompanying Check No. <u>2/223</u>. The U.S. Patent and Trademark Office is

hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Grant E. Ree

Agent for Applicants Registration No. 41,264

Date: Mush 4, 1958

1100 New York Avenue, N.W. Suite 600 Washington, D.C. 20005-3934 (202) 371-2600

P:\USERS\HCARLSON\0725\0100001\pldg SKGF Rev. 1/26/98 clp